Firstly, that doesn't include the $12M R&D rebate from the previously financial year and secondly you stated "They didn't have to rely on vulture capitalists to keep the lights on another few months." so you were talking about the CN and warrants which is $46M in total so is nearly 3 quarters and not another few months.
At the end of the day, the clinical trial updates will determine the pps and the market somehow hasn't place any valuation from the excellent clinical trial update for VAXINIA were the data allow Fast Track designation and ODD within only 12-18 months and excellent clinical trial update for Azer-Cel with the medical publication accepted in a major conference. So my eyes tell me the stock is very undervalue now as the market isn't always right.
IMU Price at posting:
3.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)